Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company developing antiviral therapeutics that target the replication machinery of viruses such as influenza viruses, coronaviruses, noroviruses and hepatitis C viruses. This news page compiles company announcements, press releases and regulatory disclosures so readers can follow Cocrystal’s scientific, clinical and corporate developments over time.
Visitors can review updates on CDI-988, Cocrystal’s oral pan-viral 3CL protease inhibitor being advanced as a potential prevention and treatment for norovirus infections and for coronavirus infections. Recent news has highlighted FDA Investigational New Drug (IND) clearance, a Study May Proceed Letter for a Phase 1b human challenge study, Institutional Review Board approval at Emory University School of Medicine, and previously reported favorable Phase 1 safety and tolerability data.
The feed also covers progress in the company’s influenza programs, including oral and inhaled CC-42344 for pandemic and seasonal influenza A and an influenza A/B polymerase complex program supported by a National Institutes of Health Small Business Innovation Research (SBIR) Phase I award. Articles describe human challenge studies, preclinical findings against highly pathogenic avian influenza strains and external validation through government funding.
In addition to R&D news, this page includes capital markets and corporate updates, such as registered direct offerings, private placements of common stock and warrants, and conference presentations where Cocrystal’s leadership provides company overviews and clinical progress updates. Investors and observers can use this centralized news stream to follow key milestones, including clinical trial initiations, data presentations, grant awards and financing transactions related to COCP.
Cocrystal Pharma (Nasdaq: COCP) announced that the U.S. FDA granted Fast Track designation to CDI-988, an oral direct-acting protease inhibitor being developed to prevent and treat norovirus infection. The designation enables earlier FDA interactions, rolling NDA review, and potential Priority Review.
CDI-988 targets a conserved 3CL protease region; a Phase 1b norovirus challenge study is currently underway at Emory University to evaluate both prevention and treatment.
Cocrystal Pharma (Nasdaq: COCP) reported 2025 results and pipeline updates on March 31, 2026. The company began a Phase 1b norovirus human challenge study at Emory for oral protease inhibitor CDI-988.
Key 2025 financials: R&D $5.1M (vs $12.5M), G&A $4.0M (vs $5.3M), net loss $8.8M ($0.78/share, vs $17.5M), cash $7.7M (vs $9.9M), working capital $5.9M, and 11.3M shares outstanding.
Cocrystal Pharma (Nasdaq: COCP) announced first subjects dosed in a Phase 1b randomized, double-blind, placebo-controlled human challenge study evaluating oral antiviral CDI-988 for prevention and treatment of norovirus. The study at Emory will enroll up to 40 healthy adults aged 18–49 infected with GII.2 (Snow Mountain Virus).
Primary endpoint: reduction in clinical symptom incidence versus placebo. Secondary endpoints: viral shedding, disease severity, safety, and pharmacokinetics. CDI-988 previously showed favorable Phase 1 safety; FDA issued a Study May Proceed letter in Sept 2025 and Emory IRB approved the study in Dec 2025. No approved norovirus treatments exist; norovirus causes an estimated $60 billion annual global economic burden.
Cocrystal Pharma (Nasdaq: COCP) will present initial Phase 1 and ongoing Phase 1b norovirus challenge study data for CDI-988 at ICAR2026, April 27–May 1 in Prague.
CDI-988 is described as the company’s first oral, direct-acting protease inhibitor developed for prevention and treatment of acute norovirus gastroenteritis and as a pan-viral 3CL protease inhibitor.
Cocrystal Pharma (Nasdaq: COCP) received Institutional Review Board approval from Emory University School of Medicine to start a Phase 1b human challenge study of CDI-988 for prevention and treatment of norovirus.
Key facts: the study follows FDA IND clearance and a Study May Proceed letter, will enroll up to 40 healthy adults (ages 18-49), use norovirus GII.2 challenge, and expects subject enrollment in Q1 2026. Primary endpoint is reduction in clinical symptoms; secondary endpoints include viral shedding and disease severity.
Cocrystal Pharma (Nasdaq: COCP) will present at Noble Capital Markets’ 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 AM ET. James Martin, CFO and co-CEO, will give a company overview and a clinical progress update at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida.
A video webcast of the presentation will be posted on December 4, 2025 on the company website and will be archived for 90 days. Interested investors can attend the conference at a discounted rate using code COCPNOBLECON.
Cocrystal Pharma (Nasdaq: COCP) reported Q3 2025 results and pipeline updates on Nov 14, 2025. The company received FDA IND clearance to evaluate oral protease inhibitor CDI-988 as a norovirus preventive and treatment and expects to start a Phase 1b norovirus challenge study in Q1 2026. Cocrystal also received a $500,000 NIH SBIR award for an influenza A/B program and completed recent financings, including $4.7M gross from a registered direct offering and a $1.03M private placement.
Q3 results: net loss $2.0M ($0.19/sh); nine‑month net loss $6.4M ($0.61/sh). Unrestricted cash was $7.7M as of Sept 30, 2025; working capital $7.3M.
Cocrystal Pharma (Nasdaq: COCP) completed a private placement on October 30, 2025 raising $1.03 million by selling 743,024 common shares at $1.39 per unit and issuing unregistered warrants to buy up to 1,486,048 shares at an exercise price of $1.24. The warrants are exercisable upon issuance and expire in 27 months. Four investors were company insiders and directors, including Phillip Frost, Fred Hassan, Richard Pfenniger and co-CEO/CFO James Martin. If all warrants are exercised for cash, the company would receive approximately $1.83 million more. The company said net proceeds will support clinical development programs, working capital and general corporate purposes. The securities were offered under Section 4(a)(2) and Regulation D and are unregistered.
Cocrystal Pharma (Nasdaq: COCP) announced on October 27, 2025 that it received a NIH/NIAID SBIR Phase I award of approximately $500,000 to support development of a novel, oral, broad‑spectrum antiviral candidate for influenza A and B. The funds will be used to characterize lead molecules that inhibit an essential function of the influenza polymerase complex. The award is non‑dilutive and intended to assess scientific, technical and commercial potential; successful Phase I completion may enable application for a larger Phase II award. The research is supported under award number 75N93025C00038. Management highlighted the award as validation of its structure‑based drug discovery platform and part of a strategy to secure additional non‑dilutive capital.
Cocrystal Pharma (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 9, 2025 at 12:00 pm Eastern time.
The presentation will include a company overview followed by a Q&A session. Investors can access the live presentation through registration, and a video webcast will be available on the company's website within 48 hours of the event, remaining accessible for 90 days. Additionally, Mr. Martin will be available for one-on-one meetings with qualified investors during the conference.